Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02628028 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3337641 in Rheumatoid Arthritis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 286
- Enrollment target
NCT02628028 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 286 participants.
The verdict
NCT02628028, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 286 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and effectiveness of LY3337641 in adults with rheumatoid arthritis (RA).
Interventions
- DRUG Placebo
- DRUG LY3337641
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2016-08-22 |
| Est. Completion | 2018-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02628028
The ClinicalTrials.gov registry entry for NCT02628028 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02628028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02628028 about?
NCT02628028 is a clinical study titled "A Study of LY3337641 in Rheumatoid Arthritis". The main purpose of this study is to evaluate the safety and effectiveness of LY3337641 in adults with rheumatoid arthritis (RA).
What is the current status of trial NCT02628028?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 286 participants. The study started on 2016-08-22. Estimated completion is 2018-08-15.
What interventions are being tested in trial NCT02628028?
The interventions under investigation include: Placebo (DRUG), LY3337641 (DRUG).
Who is sponsoring clinical trial NCT02628028?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.